ATE442842T1 - Verwendung von urokinase-inhibitoren zur behandlung und/oder vorbeugung von amyotrophischer lateralsklerose (als) - Google Patents

Verwendung von urokinase-inhibitoren zur behandlung und/oder vorbeugung von amyotrophischer lateralsklerose (als)

Info

Publication number
ATE442842T1
ATE442842T1 AT06754517T AT06754517T ATE442842T1 AT E442842 T1 ATE442842 T1 AT E442842T1 AT 06754517 T AT06754517 T AT 06754517T AT 06754517 T AT06754517 T AT 06754517T AT E442842 T1 ATE442842 T1 AT E442842T1
Authority
AT
Austria
Prior art keywords
inhibitors
lateral sclerosis
amyotrophic lateral
urocinasis
als
Prior art date
Application number
AT06754517T
Other languages
English (en)
Inventor
Stefan Lorenzl
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Application granted granted Critical
Publication of ATE442842T1 publication Critical patent/ATE442842T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06754517T 2005-06-24 2006-06-22 Verwendung von urokinase-inhibitoren zur behandlung und/oder vorbeugung von amyotrophischer lateralsklerose (als) ATE442842T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69343205P 2005-06-24 2005-06-24
PCT/EP2006/006029 WO2006136419A2 (en) 2005-06-24 2006-06-22 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases

Publications (1)

Publication Number Publication Date
ATE442842T1 true ATE442842T1 (de) 2009-10-15

Family

ID=37570795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754517T ATE442842T1 (de) 2005-06-24 2006-06-22 Verwendung von urokinase-inhibitoren zur behandlung und/oder vorbeugung von amyotrophischer lateralsklerose (als)

Country Status (13)

Country Link
US (1) US8093258B2 (de)
EP (2) EP1893185B1 (de)
JP (1) JP2008543900A (de)
KR (1) KR20080027875A (de)
AT (1) ATE442842T1 (de)
AU (1) AU2006261099A1 (de)
CA (1) CA2612262A1 (de)
DE (1) DE602006009257D1 (de)
ES (1) ES2329286T3 (de)
HK (1) HK1109862A1 (de)
MX (1) MX2007016439A (de)
RU (1) RU2410087C2 (de)
WO (1) WO2006136419A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967322A4 (de) * 2019-05-10 2022-06-08 Talengen International Limited Verfahren und medizin zur behandlung von amyotropher lateralsklerose

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340833A (en) 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
US5952307A (en) 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
CH689611A5 (de) 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
AUPO227896A0 (en) 1996-09-13 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Novel compounds and their preparation
US6528619B1 (en) 1997-04-11 2003-03-04 Roche Diagnostics Gmbh Inhibitors for urokinase receptor
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
EP1054886B1 (de) * 1998-02-09 2002-09-04 3-Dimensional Pharmaceuticals, Inc. Heteroaryl-amidinen,-methylamidinen und -guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren
ES2189455T3 (es) 1998-07-20 2003-07-01 Wilex Ag Nuevos agentes inhibidores de la urocinasa.
US6576613B1 (en) 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
WO2000005214A2 (en) 1998-07-24 2000-02-03 Pfizer Inc. Isoquinolines as urokinase inhibitors
ATE264678T1 (de) 1998-07-29 2004-05-15 Taiho Pharmaceutical Co Ltd Hemmer der angiogenese und der urokinase produktion und seine medizinische anwendung
WO2000017158A1 (de) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase-inhibitoren
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
DE19940389A1 (de) 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
US20030232789A1 (en) 1999-12-15 2003-12-18 Allen Darin Arthur Salicylamides as serine protease and factor xa inhibitors
US6207701B1 (en) 2000-01-28 2001-03-27 Abbott Laboratories Urokinase inhibitors
DE10013715A1 (de) 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
IL149042A0 (en) 2000-08-11 2002-11-10 Corvas Int Inc Non-covalent inhibitors of urokinase and blood vessel formation
US6586405B2 (en) 2000-08-11 2003-07-01 Corvas International, Inc. Non-covalent inhibitors of urokinase and blood vessel formation
DE50211672D1 (de) 2001-03-21 2008-03-27 Wilex Ag Urokinase-inhibitoren
WO2003048127A1 (en) 2001-12-04 2003-06-12 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
DE50209313D1 (de) 2001-12-12 2007-03-08 Wilex Ag Selektive arylguanidinpeptide als urokinaseinhibitoren
JP4898091B2 (ja) 2002-03-11 2012-03-14 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー ウロキナーゼの阻害剤、それらの製造および使用
DE10225876A1 (de) 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
US20080213244A1 (en) * 2003-05-05 2008-09-04 Wolfgang Sohngen Glutamate Receptor Antagonists as Neuroprotectives
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe

Also Published As

Publication number Publication date
WO2006136419B1 (en) 2007-05-31
WO2006136419A3 (en) 2007-04-19
EP1893185A2 (de) 2008-03-05
CA2612262A1 (en) 2006-12-28
DE602006009257D1 (de) 2009-10-29
RU2410087C2 (ru) 2011-01-27
ES2329286T3 (es) 2009-11-24
HK1109862A1 (en) 2008-06-27
EP2087885A1 (de) 2009-08-12
KR20080027875A (ko) 2008-03-28
RU2008102730A (ru) 2009-07-27
WO2006136419A2 (en) 2006-12-28
JP2008543900A (ja) 2008-12-04
MX2007016439A (es) 2008-03-04
US8093258B2 (en) 2012-01-10
EP1893185B1 (de) 2009-09-16
US20090069251A1 (en) 2009-03-12
AU2006261099A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
CY1118597T1 (el) Συνθεσεις οι οποιες περιεχουν λιπαση, πρωτεαση και αμυλαση για αντιμετωπιση παγκρεατικης ανεπαρκειας
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
DE602004023932D1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
ATE481969T1 (de) Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE521608T1 (de) Glucokinaseaktivatoren
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
MA30872B1 (fr) Compositions d'inhibiteurs de la chk1.
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE527350T1 (de) Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen
ATE529427T1 (de) Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
ATE445644T1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1893185

Country of ref document: EP